Cytopathic adenoviral E1B mutated viruses for therapy and prophy

Details Cytopathic adenoviral E1B mutated viruses for therapy and prophy Cytopathic adenoviral E1B mutated viruses for therapy and prophy

1997-12-08

2000-06-27

Guzo, David

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

4353201, 536 2372, C07H 2104, C12N 510

Patent

active

060805781

ABSTRACT:
Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.

REFERENCES:
patent: 5677178 (1997-10-01), McCormick

Affiliated with

Also associated with

Rating

Cytopathic adenoviral E1B mutated viruses for therapy and prophy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cytopathic adenoviral E1B mutated viruses for therapy and prophy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytopathic adenoviral E1B mutated viruses for therapy and prophy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1783434